U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. Peptides for HIV-1 Infection Detection Assay for Seroconverted HIV-1 Vaccine Recipients
  1. Licensing and Collaboration Opportunities

Peptides for HIV-1 Infection Detection Assay for Seroconverted HIV-1 Vaccine Recipients

Peptides have been identified which are useful in the diagnosis of HIV infection. These peptides detect antibodies against HIV during natural infection and differentiate antibodies from true HIV infection from antibodies elicited in response to an HIV vaccine. Due to the increasing complexity of HIV-1 vaccine candidates, most people who get vaccinated are expected to show positive results when tested with licensed HIV-1 detection assays. Vaccine recipients may thus be falsely diagnosed as HIV positive and face a range of social and economic harms (e.g. employment, insurance, recruitment to the armed forces, travel, immigration, blood donations). These peptides are thus useful as serodiagnostic reagents for differentiation in order to distinguish between HIV infected individuals and individuals participating in HIV vaccine trials.

Potential Commercial Applications:

  • Peptides can be used in the diagnosis of HIV infection
  • Peptides can be used for differential diagnosis to distinguish between individuals naturally infected with HIV and individuals participating in HIV vaccine clinical trials

Competitive Advantages:

  • These peptides can be used in HIV vaccine trials to help establish vaccine effectiveness vs. failure
  • Will reduce stigmatization of healthy vaccine trial participants and improve recruitment efforts
  • May be useful in blood collection centers in order to accept appropriate blood donors (uninfected vaccine recipients)
  • Support blood supply when HIV vaccines are licensed

Surender Khurana
Hana Golding

Intellectual Property:
US Patent No. 7,888,003
US Patent No. 8,722,324
PCT Application No. PCT/US2005/031287
PCT Application No. PCT/US2010/035801
Related International patent applications filed and patents issued

Licensing Contact:
Bill Ronnenberg, JD-MIP, MS
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
Email: FDAInventionlicensing@fda.hhs.gov
Phone: 240-402-4561

OTT Reference No: E-2004-030
Updated: September 22, 2015

Back to Top